Background: Although early treatment is valuable in the prognosis of crush syndrome, the diagnosis and treatment of many victims are inevitably delayed in major disasters. Patients and Methods: Among the 38 victims of the Marmara earthquake with crush injury, 27 were diagnosed as crush syndrome on the basis of findings of acute renal failure. Intensive intravenous fluid treatment was started in all patients on admission. Of these 27 patients, 10 required dialysis treatment while 17 did not. The laboratory data on admission were evaluated and compared between the two groups. Results: The mean admission time of 27 patients was 46.5 ± (SE) 3.08 h. There was no significant difference between the dialysis and the nondialysis groups with regard to patient’s age, trapped time or admission time. A significantly higher number of patients had crush injury in more than one extremity in the dialysis group. The dialysis group had significantly lower systolic blood pressure, central venous pressure but a higher heart rate together with higher levels of serum urea nitrogen, creatinine, creatinine kinase, C-reactive protein, fibrinogen on admission compared to the nondialysis group. Conclusion: Our results suggest that even delayed application of aggressive specific fluid treatment under close monitoring may prevent the development of established acute renal failure.

Better OS, Stein JH: Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990;372:825–829.
Michaelson M: Crush injury and crush syndrome. World J Surg 1992;16:899–903.
Abassi ZA, Hoffman A, Better OS: Acute renal failure complicating muscle crush injury. Semin Nephrol 1998;18:558–565.
Better OS: Acute renal failure in casualties of mass disasters. Kidney Int 1993;43(suppl 41):S235–S236.
Ron D, Taitelman U, Michaelson M, Bar-Joseph G, Bursztein S, Better OS: Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med 1984;144:277–280.
Shimazu T, Yoshioka T, Nakata Y, Ishikawa K, Mizushima Y, Morimoto F, Kishi M, Takaoka M, Tanaka H, Iwai A, Hiraide A: Fluid resuscitation and systemic complications in Crush Syndrome: 14 Hanshin-Awaji earthquake patients. J Trauma 1997;42:641–646.
Guha-Sapir D, Carballo M: Disaster in Turkey: Lessons for health preparedness. Lancet 1999;354:1649.
Sever MS, Erek E, Vanholder R, Akoglu E, Yavuz M, Ergin H, Tekce M, Korular D, Tulbek MY, Keven K, van Vlem B, Lameire N: The Marmara earthquake: Epidemiological analysis of the victims with nephrological problems. Kidney Int 2001;60:1114–1123.
Better OS: The crush syndrome revisited (1940–1990). Nephron 1990;55:97–103.
Kazancioglu R, Korular D, Sever MS, Türkmen A, Aysuna N, Kayacan SM, Tahin S, Yildiz A, Bozfakioglu S, Ark E: The outcome of patients presenting with crush syndrome after the Marmara earthquake. Int J Artificial Organs 2001;24:17–21.
Iskit SH, Alpay H, Tugtepe H, Özdemir C, Ayyildiz SH, Özel K, Bayramiçli M, Tetik C, Dagli TE: Analysis of 33 pediatric trauma victims in the 1999 Marmara, Turkey earthquake. J Pediatr Surg 2001;36:368–372.
Oda Y, Shindoh M, Yukioka H, Nishi S, Fujimori M, Asada A: Crush syndrome sustained in the 1995 Kobe, Japan earthquake: Treatment and outcome. Ann Emergency Med 1997;30:507–512.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.